Conference LibraryGated
EsoBiotec SA · ENaBL platform · ESO-T01 (acquired by AstraZeneca)
比利时 in vivo CAR-T 公司,ENaBL (Engineered NanoBody Lentiviral) 第三代 immune-shielded lentiviral vector 平台。ESO-T01 是其首款 BCMA-targeted CAR-T candidate(in vivo · 治疗 multiple myeloma)。 2025-03 被 AstraZeneca $1B 收购。 对 SunVax 的对标维度: - delivery modality (lentiviral vs SunVax LNP) → DIFFEREN…
- Type
- company
- Domain
- conference
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- in_vivo_car_t_lentiviral
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "ESO-T01 early IIT clinical data · not validated late-stage clinical efficacy"
- threat_level
- complementary
- competes_dimensions
- in_vivo_cell_engineering
- platform_tech
- ENaBL (Engineered NanoBody Lentiviral) · third-generation, non-replicative, self-inactivating, immune-shielded lentiviral vector · T cell-specific synthetic pro
- hq_location
- Mont-Saint-Guibert, Belgium
- acquisitions
- [object Object]
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.